AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.
Mondi, A., Fabbiani, M., Ciccarelli, N., Colafigli, M., D'avino, A., Borghetti, A., Gagliardini, R., Cauda, R., De Luca, A., Di Giambenedetto, S., Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study, <<JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY>>, 2015; 70 (6): 1843-1849. [doi:10.1093/jac/dkv037] [http://hdl.handle.net/10807/68424]
Autori: | |
Titolo: | Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1093/jac/dkv037 |
Data di pubblicazione: | 2015 |
Abstract: | AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up. |
Lingua: | Inglese |
Rivista: | |
Citazione: | Mondi, A., Fabbiani, M., Ciccarelli, N., Colafigli, M., D'avino, A., Borghetti, A., Gagliardini, R., Cauda, R., De Luca, A., Di Giambenedetto, S., Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study, <<JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY>>, 2015; 70 (6): 1843-1849. [doi:10.1093/jac/dkv037] [http://hdl.handle.net/10807/68424] |
Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |